摘要
目的观察孟鲁司特钠治疗病毒性小儿哮喘的临床疗效及安全性。方法选取2020年5月-2021年5月在我院诊治的84例病毒性小儿哮喘作为研究对象,采用随机数字表法分为对照组和观察组,各42例。对照组采用常规治疗,观察组在对照组基础上给予孟鲁司特钠治疗。比较两组治疗总有效率、症状消失时间、症状评分、不良反应发生情况、哮喘发作次数及复发率。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组气喘、咳嗽消失时间短于对照组,差异有统计学意义(P<0.05);两组气喘、咳嗽、睡眠、运动后咳嗽或哮喘评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05);观察组平均哮喘发作次数、复发率均小于对照组,差异有统计学意义(P<0.05)。结论孟鲁司特钠治疗病毒性小儿哮喘临床疗效确切,可缩短患儿症状消失时间,临床不良反应少,且减少哮喘发作次数,预防疾病复发。
Objective To observe the clinical efficacy and safety of montelukast sodium in the treatment of viral asthma in children.Methods A total of 84 children with viral asthma treated in our hospital from May 2020 to May 2021 were selected as the research objects.They were divided into control group and observation group by random number table method,42 cases in each group.The control group was treated with conventional therapy,and the observation group was treated with montelukast sodium on the basis of the control group;the total effective rate,symptom disappearance time,symptom score,adverse reactions,asthma attack frequency and recurrence rate were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The disappearance time of asthma and cough in the observation group was less than that in the control group,and the difference was statistically significant(P<0.05).The scores of asthma,cough,sleep,cough or asthma after exercise in the two groups were lower than those before treatment,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).The average number of asthma attacks and recurrence rate in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Montelukast sodium is effective in the treatment of viral asthma in children,which can shorten the disappearance time of symptoms in children,reduce the number of asthma attacks,and prevent disease recurrence.
作者
张广平
ZHANG Guang-ping(Department of Pediatrics,Qingyang County People's Hospital,Qingyang 242800,Anhui,China)
出处
《医学信息》
2021年第23期105-107,共3页
Journal of Medical Information
关键词
孟鲁司特钠
异丙托溴铵
病毒性小儿哮喘
咳嗽
Montelukast sodium
Ipratropium bromide
Viral asthma in children
Cough
